What is the role of mirabegron in the treatment of overactive bladder (OAB) in children?

Updated: Apr 01, 2019
  • Author: Pamela I Ellsworth, MD; Chief Editor: Edward David Kim, MD, FACS  more...
  • Print

Mirabegron is a beta 3 adrenoreceptor agonist approved for use in the management of OAB in adults. It facilitates relaxation of the bladder. It has not been approved for use in children.

In a prospective pilot study in 58 pediatric patients (median age 10.1 years), mirabegron appeared to be a safe and effective alternative for children with idiopathic OAB who had experienced no symptom improvement with behavioral and medical therapies and/or had significant side effects with at least two different antimuscarinic agents. After a median 11.5 months of treatment, median bladder capacity improved from 150 to 200 mL (P < 0.001). Continence improved in 52 of the 58 patients, with 13 being completely dry. Eight patients reported mild to moderate side effects. [41]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!